Apogee Therapeutics, Inc.
APGE
Pozycja w akcjach
#2356
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Cena akcji
$135.07
Ostatnia synchronizacja: 2026-09-04
Kapitalizacja rynkowa
$8.36B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
144.91%
Kraj
US
Handel Apogee Therapeutics, Inc. (APGE)
Kategoria
Healthcare
EPS dla Apogee Therapeutics, Inc. (APGE)
EPS na dzień June 2026 TTM: $-4.34
Według najnowszych raportów finansowych i ceny akcji firmy Apogee Therapeutics, Inc., obecny EPS (TTM) wynosi $-4.34. Na koniec roku 2023 firma miała EPS w wysokości $-1.66, wzrost w porównaniu do do EPS z roku 2022, który wynosił $-0.79.
Historia EPS dla Apogee Therapeutics, Inc. od 2022 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-4.34 | 31.52% |
| 2024 | $-3.30 | 98.80% |
| 2023 | $-1.66 | 110.13% |
| 2022 | $-0.79 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -499.08% |
US
|
|
| $-7.98 | 83.87% |
US
|
|
| $-5.29 | 21.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -739.17% |
NL
|
